FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma
FDA approves olaparib for gBRCAm metastatic pancreatic adenocarcinoma
Related Articles
Tribal Affairs
FDA engagement with American Indian and Alaska Native tribal governments – Resources for tribal governments
Benchmarks for Diversity in Oncology Clinical Trials
Co-Sponsored by the Oncology Center of Excellence and American Cancer Society (ACS)
Index of application status transparency and availability of public information for Project Orbis agencies
The purpose of this paper is to provide a guideline for understanding and comparing the regulatory framework of Project Orbis Partners (POPs) and Project Orbis…
Benchmarks for Diversity in Oncology Clinical Trials
Co-Sponsored by the Oncology Center of Excellence and American Cancer Society (ACS)
Conversations on Cancer: National Hispanic/Latino Family Cancer Awareness Week
The FDA Oncology Center of Excellence Project Community will hold its inaugural National Hispanic Family Cancer Awareness Week, from September 20 through 26,…
October 15, 2024: 2024 FDA Oncology Center of Excellence Pediatric
The FDA Oncology Center of Excellence (OCE) Pediatric Oncology Program cordially invites members of the pediatric oncology advocacy community to participate in this forum to…
OCE Conversations on Cancer, Pazdur+25—Celebrating a Silver FDA Anniversary
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Benchmarks for Diversity in Oncology Clinical Trials
Co-Sponsored by the Oncology Center of Excellence and American Cancer Society (ACS)
Conversations on Cancer: National Hispanic/Latino Family Cancer Awareness Week
The FDA Oncology Center of Excellence Project Community will hold its inaugural National Hispanic Family Cancer Awareness Week, from September 20 through 26,…
Benchmarks for Diversity in Oncology Clinical Trials
Co-Sponsored by the Oncology Center of Excellence and American Cancer Society (ACS)